zika
viru
zikv
mosquitoborn
flaviviru
reemerg
seriou
public
health
problem
around
world
syndrom
infect
peopl
rang
asymptomat
infect
sever
neurolog
disord
guillainbarr
e
syndrom
microcephali
screen
antizikv
drug
deriv
chines
medicin
herb
one
method
identifi
antivir
agent
paper
report
cephalotaxin
cet
alkaloid
isol
cephalotaxu
drupacea
effect
inhibit
zikv
activ
vitro
ie
vero
cell
line
mechan
underli
effect
involv
virucid
activ
decreas
viral
replic
specif
cet
found
decreas
zikv
rna
viral
protein
express
inhibit
zikv
replic
inhibit
zikv
mrnaprotein
product
also
determin
cet
effect
inhibit
dengu
viru
taken
togeth
find
indic
cet
could
effect
lead
compound
treatment
zikv
also
suggest
investig
develop
cetderiv
drug
may
lead
new
class
antiflaviviru
medic
zika
viru
zikv
mosquitoborn
envelop
rna
viru
belong
flaviviru
genu
flavivirida
famili
famili
hepat
c
viru
hcv
dengu
viru
denv
west
nile
viru
wnv
yellow
fever
viru
yfv
japanes
enceph
viru
jev
also
belong
zikv
first
isol
rhesu
monkey
near
zika
forest
uganda
viral
genom
zikv
encod
polyprotein
consist
capsid
premembranemembran
envelop
seven
nonstructur
protein
b
recent
year
zikv
infect
becom
seriou
escal
threat
global
health
exampl
zikv
spread
rapidli
least
region
countri
central
south
america
brazil
becom
epidem
affect
million
peopl
zikv
infect
associ
sever
neurolog
complic
guillainbarr
e
syndrom
adult
microcephali
infant
prior
outbreak
affect
brazil
central
south
american
countri
zikv
infect
consid
lead
mild
diseas
howev
outbreak
identifi
pregnant
women
infect
zikv
babi
born
seriou
birth
defect
fetal
growth
restrict
well
neurolog
ocular
abnorm
case
zikv
pregnanc
even
led
perinat
death
zikv
also
known
caus
benign
febril
ill
approxim
infect
individu
ill
lead
symptom
similar
arboviru
infect
includ
denv
chikungunya
viru
chikv
specif
symptom
includ
fever
rash
joint
pain
conjunct
less
commonli
headach
vomit
jaundic
clinic
symptom
typic
zikv
infect
includ
fever
headach
joint
pain
conjunct
macular
atrophi
februari
world
health
organ
declar
zikv
public
health
emerg
intern
concern
pheic
strategi
fight
zikv
infect
includ
develop
vaccin
screen
antivir
agent
inhibit
differ
stage
viral
life
cycl
unfortun
approv
antivir
zikv
agent
current
avail
thu
urgent
need
develop
safe
effect
antivir
agent
zikv
elucid
mechan
help
identifi
lead
compound
potenti
clinic
develop
fight
zikv
cephalotaxin
cet
harringtonin
ht
homoharringtonin
hht
isoharringtonin
deoxyharringtoninea
alkaloid
isol
purifi
chines
conifer
tree
cephalotaxu
hainanensi
cet
shown
promis
antivir
activ
hepat
b
also
found
antileukem
activ
due
wide
rang
effect
cet
drug
also
believ
great
potenti
treatment
diseas
includ
cancer
ht
inhibit
chikv
replic
downregul
viral
protein
express
hht
show
activ
hbv
coronaviru
previou
research
determin
ht
hht
promis
candid
treatment
diseas
relat
varicellazost
viru
vzv
although
drug
similar
structur
substitu
vari
wide
may
translat
differ
pharmacolog
activ
therefor
current
studi
opt
investig
potenti
antizikv
activ
cet
vero
cell
result
indic
cet
inde
possess
antizikv
activ
thu
also
opt
investig
potenti
mechan
underli
antizikv
activ
cet
demonstr
cet
disrupt
viral
life
cycl
prevent
zikv
replic
exhibit
virucid
activ
zikv
find
suggest
cet
potenti
develop
therapeut
agent
zikv
studi
use
vero
african
green
monkey
kidney
cell
human
lung
carcinoma
epitheli
cell
cell
cell
permiss
zikv
replic
vero
cell
cultur
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
c
co
viru
stock
determin
use
fluoresc
focu
unit
assay
store
c
use
cet
puriti
purchas
natur
product
manufactur
chemfac
wuhan
econom
technolog
develop
zone
china
dissolv
dimethyl
sulfoxid
dmso
mm
stock
solut
store
c
use
time
use
stock
solut
dilut
dmem
desir
work
concentr
reach
moreov
volum
dmso
work
concentr
adjust
concentr
dmso
everi
solut
order
avoid
solvent
interfer
among
group
cell
viabil
profil
cettreat
cell
assess
use
cell
count
kit
dojindo
laboratori
kumamoto
japan
accord
manufactur
protocol
briefli
monolay
vero
cell
plate
micropl
variabl
concentr
cet
ad
triplic
well
vero
cell
incub
c
h
end
incub
period
cultur
medium
discard
ml
fresh
medium
contain
ml
solut
ad
well
h
optic
densiti
treat
cell
measur
nm
use
biotek
synergi
multimod
micropl
reader
valu
treat
cell
normal
untreat
cell
confluent
monolay
vero
cell
seed
micropl
infect
serial
dilut
viru
medium
follow
h
infect
period
cell
overlaid
dmem
contain
methylcellulos
fb
incub
two
day
viral
fluoresc
foci
visual
count
use
invert
fluoresc
microscop
olympu
confluent
monolay
vero
cell
plate
micropl
incub
h
subsequ
ml
dmem
contain
fb
variou
concentr
cet
foci
form
unit
ffu
zikv
ad
cell
follow
incub
anoth
h
cell
wash
twice
phosphat
buffer
salin
pb
treat
cet
addit
h
anoth
twoday
incub
period
supernat
harvest
viral
titer
contain
therein
determin
use
ifa
rel
quantif
zikv
rna
vero
cell
determin
use
quantit
revers
transcript
pcr
qrtpcr
total
rna
cell
extract
h
cet
treatment
use
trizol
reagent
ambion
gene
express
quantifi
use
onestep
qrtpcr
sybr
green
kit
bioman
cat
accord
manufactur
instruct
primer
sequenc
use
zikv
denv
bactin
shown
supplementari
tabl
specif
qrtpcr
perform
plate
absorb
measur
use
roch
lightcycl
roch
appli
scienc
indianapoli
measur
obtain
triplic
bactin
use
intern
control
rel
quantif
gene
express
determin
use
method
infect
cell
fix
use
paraformaldehyd
h
wash
three
time
pb
cell
stain
antiflaviviru
envelop
antibodi
room
temperatur
h
wash
pb
cell
stain
alexa
fluor
goat
antimous
igg
jackson
immunoresearch
laboratori
inc
final
pb
wash
cell
observ
use
invert
fluoresc
microscop
olympu
determin
stage
viral
life
cycl
cet
act
upon
compar
effect
fulldur
treatment
cotreat
pretreat
posttreat
group
via
time
addit
assay
confluent
vero
cell
plate
micropl
indic
concentr
cet
ad
medium
variou
time
point
follow
fulldur
treatment
group
cet
ad
throughout
infect
period
cotreat
group
cet
ad
initi
point
zikv
infect
posttreat
group
cet
ad
zikv
infect
pretreat
group
cet
ad
h
zikv
infect
follow
zikv
infect
vero
cell
treatment
group
incub
c
h
point
level
intracellular
viral
rna
compar
vehicl
group
use
qrtpcr
intracellular
viral
envelop
protein
level
measur
western
blot
briefli
infect
cell
lysat
treat
differ
concentr
cet
harvest
h
infect
immunoblot
perform
use
antiflaviviru
envelop
antibodi
ascit
produc
inhous
antibactin
santa
cruz
biotechnolog
dalla
texa
usa
primari
antibodi
well
antimous
antihuman
horseradish
peroxidaseconjug
antibodi
secondari
antibodi
target
protein
detect
use
ecl
reagent
imag
obtain
use
uvp
chemiluminesc
machin
cellfre
antizikv
activ
cet
investig
incub
zikv
suspens
contain
ffu
indic
concentr
cet
c
h
treat
supernat
dilut
dmem
ad
confluent
vero
cell
viral
titer
determin
count
viral
fluoresc
foci
use
previous
describ
ifa
method
antivir
effect
cet
evalu
hawaii
strain
strain
strain
strain
briefli
confluent
vero
cell
seed
micropl
infect
ffu
incub
indic
concentr
cet
h
follow
dosedepend
viral
rna
reduct
assay
perform
use
qrtpcr
determin
whether
cet
effect
inhibit
viral
replic
statist
analysi
perform
use
graphpad
prism
softwar
data
express
mean
standard
deviat
triplic
experi
statist
signific
data
assess
use
twotail
student
ttest
p
valu
consid
signific
earlier
research
found
cet
abl
inhibit
hbv
infect
howev
antivir
effect
cet
virus
previous
investig
studi
first
use
vero
cell
investig
antizikv
abil
cet
vero
cell
cell
seed
plate
overnight
infect
zikv
ffu
per
well
h
incub
zikv
indic
concentr
cet
cell
fix
stain
antibodi
react
flavivirus
follow
quantif
result
demonstr
cet
mm
significantli
inhibit
zikv
infect
dosedepend
manner
fig
b
viabil
cettreat
vero
cell
determin
use
assay
comparison
result
control
group
reveal
cet
possess
mild
cytotox
cc
cet
though
found
mm
fig
howev
cet
fdaapprov
drug
concern
lack
safeti
verifi
antizikv
abil
inhibit
level
cet
qrtpcr
western
blot
ffu
assay
perform
vero
cell
seed
plate
overnight
infect
ffu
zikv
per
well
incub
indic
concentr
cet
h
qrtpcr
western
blot
ffu
assay
employ
result
qrtpcr
show
cet
inhibit
zikv
infect
dosedepend
manner
fig
particular
concentr
mm
cet
found
suppress
approxim
zikv
rna
product
furthermor
vero
cell
infect
ffu
zikv
per
well
indic
dosag
cet
h
incub
result
western
blot
analysi
reveal
zikv
protein
express
significantli
reduc
cet
treatment
fig
result
ffu
assay
reveal
cet
abl
decreas
zikv
progeni
yield
dosedepend
manner
fig
taken
togeth
evid
indic
cet
effect
suppress
zikv
propag
data
indic
cet
abl
inhibit
zikv
infect
decreas
viral
rna
protein
progeni
yield
therefor
investig
mechan
underli
abil
cet
inhibit
zikv
perform
time
addit
assay
mm
cet
ad
vero
cell
pretreat
cotreat
posttreat
fulldur
treatment
group
cell
group
infect
ffu
zikv
per
well
h
follow
end
infect
period
cell
wash
two
time
medium
replac
h
incub
cell
lyse
rna
analysi
supernat
collect
ffu
assay
result
analysi
reveal
cet
like
affect
late
stage
zikv
infect
fig
b
mean
inhibitori
effect
cet
like
occur
viru
entri
investig
cet
inhibit
zikv
entri
vero
cell
infect
zikv
wash
pb
remov
virus
infect
cell
treat
indic
concentr
cet
cell
lysat
supernat
collect
h
incub
analysi
result
show
administ
cet
initi
infect
ie
posttreat
group
suppress
viral
rna
replic
particular
cell
posttreat
group
administ
mm
cet
zikv
rna
level
significantli
reduc
fig
ffu
assay
reveal
viral
yield
decreas
posttreat
group
cell
administ
mm
cet
fig
addit
virucid
assay
show
cet
affect
viru
stabil
ffu
assay
cell
incub
supernat
contain
ffu
zikv
without
mm
cet
room
temperatur
h
prior
detect
reveal
cet
decreas
viru
level
h
incub
fig
confirm
cet
like
possess
abil
influenc
viru
stabil
assess
abil
cet
inhibit
dengu
viru
vero
cell
seed
plate
overnight
inocul
indic
concentr
cet
ffu
per
well
ffu
per
well
ffu
per
well
ffu
per
well
h
incub
rna
treat
cell
extract
analyz
qrtpcr
result
reveal
mm
cet
inhibit
four
serotyp
dengu
virus
dosedepend
manner
fig
therefor
cet
also
potenti
use
treatment
dengu
viru
infect
outbreak
zikv
brazil
one
uncontrol
epidem
world
experienc
sinc
zikv
becom
flaviviru
great
medic
concern
nonetheless
date
despit
signific
effort
develop
effect
vaccin
effect
treatment
emerg
pathogen
found
therefor
identifi
broadspectrum
antivir
drug
effect
clinic
compound
critic
treatment
zikv
patient
control
zikv
outbreak
cet
deriv
ester
compound
ht
hht
found
possess
activ
leukem
cell
antitumor
abil
compound
believ
aris
inhibitori
effect
protein
synthesi
previou
research
also
determin
cet
ester
deriv
inhibitori
effect
hbv
vzv
chikv
howev
first
studi
demonstr
cet
inhibit
zikv
infect
specif
result
ifa
reveal
cet
treatment
reduc
viral
infect
vero
cell
fig
research
previous
assess
viabil
cell
etbr
cell
treat
cet
found
cet
cytotox
wherea
induc
dosedepend
antihbv
antibovin
viral
diarrhoea
viru
bvdv
surrog
hcv
effect
respect
result
also
demonstr
cet
possess
low
cytotox
affect
cell
viabil
fig
moreov
viral
rna
level
protein
express
level
viral
titer
fig
c
cettreat
vero
cell
reveal
mm
cet
led
viru
inhibit
consist
previou
find
previou
studi
demonstr
ht
hht
inhibit
replic
chikv
vzv
sindbi
viru
sinv
hht
shown
exert
antivir
effect
coronaviru
cov
hbv
ht
hht
abl
inhibit
replic
rna
dna
virus
indic
antivir
activ
like
due
cellular
rather
viral
factor
cellular
factor
essenti
viral
replic
cet
ester
shown
interfer
rna
translat
block
bind
aminoacyltrna
acceptor
site
larg
ribosom
subunit
therebi
also
block
subsequ
format
peptid
bond
moreov
ht
found
limit
replic
chikv
inhibit
larg
ribosom
subunit
subsequ
downregul
translat
viral
protein
similar
previou
studi
result
time
addit
assay
show
cet
affect
late
stage
zikv
infect
fig
b
sought
determin
possibl
mechan
cet
influenc
zikv
rna
replic
previou
research
investig
vzv
determin
ht
hht
like
employ
mechan
inhibit
zikv
exampl
ht
hht
like
inhibit
lytic
gene
express
replic
may
turn
interfer
signal
transduct
pathway
transcript
factor
involv
vzv
lytic
gene
express
hand
herpesvirus
hhv
ht
hht
abl
block
cell
cycl
progress
transit
turn
affect
lytic
gene
express
replic
thu
mechan
ht
hht
cet
inhibit
vzv
replic
may
involv
disrupt
cell
cycl
infect
cell
virolog
rna
level
indic
viru
replic
antidengu
abil
cet
determin
use
qrtpcr
data
shown
repres
mean
sd
statist
signific
determin
via
ttest
compar
dengu
viru
group
indic
p
indic
p
indic
p
fig
ffu
level
indic
viru
releas
fig
current
studi
posttreat
group
ie
vero
cell
receiv
cet
zikvinfect
decreas
observ
viral
replic
viral
releas
suggest
primari
mechan
cet
inhibit
zikv
involv
viral
replic
viru
releas
howev
time
addit
assay
show
viral
yield
fulldur
treatment
group
lower
posttreat
group
approxim
log
fig
find
suggest
cet
disrupt
viral
replic
may
also
possess
antizikv
activ
determin
perform
virucid
assay
cet
result
confirm
cet
decreas
viral
stabil
therebi
reduc
viral
yield
fig
summari
data
indic
cet
abl
inhibit
zikv
infect
affect
viral
replic
viral
stabil
final
also
studi
effect
cet
four
differ
dengu
viru
serotyp
found
cet
reduc
denv
rna
level
vero
cell
model
cet
inhibit
four
dengu
viru
serotyp
dosedepend
manner
fig
therefor
cet
may
also
use
treatment
dengu
viru
infect
conclud
result
indic
cet
effect
antivir
agent
zikv
cet
exert
antizikv
activ
inhibit
viral
product
replic
well
virucid
activ
evid
report
support
studi
cet
candid
compound
zikv
treatment
none
